Liver Health

Liver Disease Patients Could See Promising Results With Baby Aspirin

A new clinical trial found that baby aspirin could reduce the amount of liver fat in patients with metabolic dysfunction-associated steatotic liver disease.
Liver Disease Patients Could See Promising Results With Baby Aspirin
Shane Maritch/Shutterstock
A.C. Dahnke
|Updated:
0:00

Patients suffering from metabolic-associated liver disease could benefit from low-dose aspirin.

A new clinical trial out of Boston found that baby aspirin could reduce the amount of liver fat in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The results were recently published in the Journal of the American Medical Association.
A.C. Dahnke
A.C. Dahnke
Author
A.C. Dahnke is a freelance writer and editor residing in California. She has covered community journalism and health care news for nearly a decade, winning a California Newspaper Publishers Award for her work.